Relationship between plasma osteopontin and oxidative stress in patients with coronary artery disease

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 8, 2008, Pages 917-920

  Georgiadou, P ^a   Iliodromitis, E K ^a   Varounis, C ^a   Mavroidis, M ^b   Kolokathis, F ^a   Andreadou, I ^a   Psarras, S ^b   Capetanaki, Y ^b   Boudoulas, H ^b   Kremastinos, D Th ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Coronary artery disease; Osteopontin; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; MALONALDEHYDE; OSTEOPONTIN;

ADULT; AGE; ANGIOCARDIOGRAPHY; ARTERIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; MALONALDEHYDE BLOOD LEVEL; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; SMOKING; SPECTROPHOTOMETRY;

ADULT; AGED; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; HUMANS; LINEAR MODELS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OSTEOPONTIN; OXIDATIVE STRESS; RISK FACTORS;

EID: 48449083383     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.8.917     Document Type: Article

References (16)

1. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84(4):1381-478
2. Pucheu S, Coudray C, Vanzetto G, et al. Assessment of radical activity during the acute phase of myocardial infarction following fibrinolysis: utility of assaying plasma malondialdehyde. Free Radic Biol Med 1995;19:873-81
3. Holvoet P, Vanhaecke J, Janssens S, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998;98:1487-94
4. Fitzpatrick LA, Severson A, Edwards WD, et al. Diffuse calcification in human coronary arteries: association of osteopontin with atherosclerosis. J Clin Invest 1994;94:1597-604
5. Xie Z, Singh M, Singh K. ERK1/2 and JNKs, but not p38 kinase, are involved in reactive oxygen species-mediated induction of osteopontin gene expression by angiotensin II and interleukin-Iβ in adult rat cardiac fibroblasts. J Cell Physiol 2004;198:399-407
6. Ashizawa N, Graf K, Do YS, et al. Osteopontin is produced by rat cardiac flbroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. Clin Invest 1996;98:2218-27
7. Andreadou I, Iliodromitis EK, Mikros E, et al. Melatonin does not prevent the protection of ischemic preconditioning in vivo despite its antioxidant effect against oxidative stress. Free Rad Biol Med 2004;37:500-10
8. Isoda K, Nishikawa K, Kamezawa Y, et al. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res 2002;91:77-82
9. Ohmori R, Momiyama Y, Taniguchi H, et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003;170:333-7
10. Minoretti P, Falcone C, Calcagnino M, et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006;27:802-7
11. Kato R, Momiyama Y, Ohmori R, et al. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. Arterioscler Thromb Vasc Biol 2006;26:e1-2
12. Okamoto H. Osteopontin and cardiovascular system. Mol Cell Biochem 2007;300:1-7
13. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifujnctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007;27:2302-9
14. Partridge CR, Williams ES, Barhoumi R, et al. Novel genomic targets in oxidant-induced vascular injury. J Mol Cell Cardiol 2005;38:983-96
15. Aydin A, Orhan H, Sayal A, et al. Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control. Clin Bio Chem 2001;34:65-70
16. Seghtouchni I, Dral J and Bannier E. Oxidative stress parameters in type I, type II and insulin treated type II diabetes mellitus; insulin treatment efficiency. Clin Chem Acta 2001;321:89-96